The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
New Boron and Gadolinium Agents for Neutron Capture Therapy. The development of new drugs and treatments for cancer is highly important for improved health outcomes and the well-being of the community. This research has the potential to result in the development of new anticancer pharmaceuticals that will dramatically expand the clinical efficacy of a promising treatment for highly aggressive tumours. The innovative nature of this research will also contribute to Australia's science knowledge ....New Boron and Gadolinium Agents for Neutron Capture Therapy. The development of new drugs and treatments for cancer is highly important for improved health outcomes and the well-being of the community. This research has the potential to result in the development of new anticancer pharmaceuticals that will dramatically expand the clinical efficacy of a promising treatment for highly aggressive tumours. The innovative nature of this research will also contribute to Australia's science knowledge base, a key element in its future economic prosperity, and it will provide excellent training of young researchers for employment in the rapidly expanding field of drug design and development.Read moreRead less
Mitochondrial targeting by a new class of gadolinium agents. This research project will lead to the development of new molecular agents containing the element gadolinium which can selectively accumulate within cell mitochondria, with a long-term application in cutting-edge therapies involving X-rays or neutrons. The lanthanoid element gadolinium offers many unique opportunities for medicinal chemistry and this project will generate new knowledge in bioinorganic chemistry and synchrotron science. ....Mitochondrial targeting by a new class of gadolinium agents. This research project will lead to the development of new molecular agents containing the element gadolinium which can selectively accumulate within cell mitochondria, with a long-term application in cutting-edge therapies involving X-rays or neutrons. The lanthanoid element gadolinium offers many unique opportunities for medicinal chemistry and this project will generate new knowledge in bioinorganic chemistry and synchrotron science. The expected outcomes of this research will address many of the unresolved questions regarding mitochondrially-targeted gadolinium complexes, the first such agents specifically designed for potential long-term application in binary therapies and imaging.Read moreRead less
New frontiers in the therapeutic application of gadolinium. This research involves the design and development of new anticancer agents that will dramatically expand the clinical efficacy of a promising treatment for highly aggressive tumours. The innovative nature of this research will also contribute to Australia's science knowledge base and provide excellent training in the area of drug discovery.
Group 13 Mixed Halide-Hydride and Rare Earth Complexes - New Selective Chiral Hydridic or Low Valent Reducing Agents. This project will make a landmark contribution to two areas of metallohydride chemistry. Both studies will utilise and develop metals that have traditionally been mined and exported from these shores while concurrently imported as value added products at vastly inflated cost. This research will identify knock-on applications in order to stem this financial bias. The new paths to ....Group 13 Mixed Halide-Hydride and Rare Earth Complexes - New Selective Chiral Hydridic or Low Valent Reducing Agents. This project will make a landmark contribution to two areas of metallohydride chemistry. Both studies will utilise and develop metals that have traditionally been mined and exported from these shores while concurrently imported as value added products at vastly inflated cost. This research will identify knock-on applications in order to stem this financial bias. The new paths to rare earth (= Ln) hydrides will have broad industrial appeal, particularly for new materials, where, like similar group 13 materials, they may be used in the deposition of Ln films or even as precursors to superconducting solids. It is anticipated industrial collaboration will ensue. Australia will be promoted as a developer and innovator of frontier technologies.Read moreRead less
Thallium hydride complexes - synthesis, stabilisation and synthetic utility. Australia has abundant geological deposits of group 13 metals. The hydride chemistries of group 13 elements are critical to modern applications of these elements. There are no hydrides of thallium, the heaviest member of group 13. This project aims to prepare and stabilise thallium hydrides to enable technological applications of thallium.
Boron and silicon based pincer ligands for environmentally responsible catalysis. The production of everyday chemicals (pharmaceuticals, agrochemicals, polymers) comes at a price, economic and environmental. Metal catalysts significantly reduce the environmental impact of both the associated energy requirements and waste products. New classes of catalysts will be developed based on the unconventional elements boron and silicon.